AAIC26: Roche charts expanded course for Alzheimer’s therapy, touts long-term anti-amyloid impact
Roche is eyeing a wider patient population for its anti-amyloid Alzheimer’s hopeful, trontinemab, as the space increasingly examines the potential …
Post
-
-
MASH therapy enters a more competitive era
For much of the last two years, there has only been one real way to treat metabolic dysfunction-associated steatohepatitis (MASH). …
-
MediciNova achieves target enrolment in SEANOBI-ALS study of MN-166
MediciNova has achieved the target enrolment of 200 patients in the SEANOBI-ALS clinical study, evaluating MN-166 (ibudilast) for amyotrophic lateral …
-
Biomarkers in Nephrology Research: From Exploratory to Decision-Making Tools
While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other …
-
Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
Kairos Pharma has reported interim safety results from its ongoing Phase I clinical trial of ENV-105 (carotuximab), along with AstraZeneca's …
-
Veradermics stock jumps again on female hair loss drug win
Veradermics has seen another jump in its stock price as its hair loss drug showed benefit in women with androgenetic alopecia …
-
Smarter data, faster decisions: How biotech funding pressures are reshaping clinical development
As the biotech sector emerges from a challenging funding cycle, its effects continue to shape how companies design trials, generate …
-
Loneliness interventions do not have strong sustained effects on memory function
Loneliness, defined as a subjective experience of a discrepancy between the preferred interpersonal relationship an individual has and their actual …
-
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
Biogen’s stock has dropped after it released mixed data on its tau-targeting investigational antisense oligonucleotide (ASO), compounding a previous announcement …
-
FDA clears Atrium’s IND application to begin Corventis trial of ATR 1072
Atrium Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application …
-
Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial
Sound Pharmaceuticals has concluded subject enrolment for its second Phase III clinical trial assessing SPI-1005 in adults with probable or …
-
FDA finalises psychedelic clinical trial guidance
The US Food and Drug Administration (FDA) has finalised its formal guidance for clinical trials involving psychedelic drugs. The FDA document …
-
Arrowhead gains EU authorisation for Redemplo in evolving FCS market
Arrowhead Pharmaceuticals recently announced that the European Commission (EC) has granted marketing authorisation for Redemplo (plozasiran), an innovative apolipoprotein C …
-
AAIC26: Community co-development to guide next generation of diverse trials
Despite progress in bolstering the diversity of clinical trials within the Alzheimer’s disease space, significant barriers to true study diversity …
-
Q32 Bio reports 36-week data from SIGNAL-AA trial’s Part B in alopecia areata
Q32 Bio has reported positive 36-week top line data from Part B of the SIGNAL-AA Phase IIa trial of bempikibart …
